Executive interview – InMed Pharmaceuticals

Executive interview – InMed Pharmaceuticals

InMed Pharmaceuticals — 14 videos in collection

More on this equity

In this interview , Eric Adams, chief executive officer of InMed Pharmaceuticals, provides an overview of InMed’s differentiated biosynthesis platform and its therapeutic pipeline of cannabinoids.

InMed Pharmaceuticals (TSX: IN) is a Canada-based biopharmaceutical company focused on manufacturing and developing cannabinoids. Its biosynthesis platform has the potential to produce cannabinoids at a lower cost and with improved purity compared to currently used methods. The company is also developing a proprietary pipeline, including INM-755 for epidermolysis bullosa, a serious, debilitating orphan indication.

You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free